GlassScriptPhysician profile
David Charles Cuellar
NPI 1376519330
$342,635.79
in general payments reported to CMS, 2019-2025
41 companies · $129K in 2025
The $129K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,810 · 2020: $422 · 2021: $26K · 2022: $12K · 2023: $56K · 2024: $115K · 2025: $129K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $264K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $10K · Travel and Lodging: $8,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $263,721.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,600.00 |
| Food and Beverage | $10,018.83 |
| Travel and Lodging | $8,406.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $286,690.96 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Intuitive Surgical, INC. | $34,409.02 | 2019-2023 | Da Vinci Sp |
| Strauss Surgical USA LLC | $17,100.00 | 2025 | Mcb Bipolar Resection Generator and Electrode |
| Janssen Biotech, INC. | $674.15 | 2019-2025 | Erleada |
| Teleflex LLC | $513.39 | 2021-2025 | Urolift, Barrigel |
| Abbvie INC. | $327.00 | 2019-2023 | Lupron Depot |
| Pfizer INC. | $267.43 | 2019-2025 | |
| Astellas Pharma US INC | $242.63 | 2019-2025 | Xtandi |
| Calyxo, INC. | $238.15 | 2021-2025 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $225.97 | 2020-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $224.73 | 2024-2025 | Adstiladrin |
| Smith+Nephew, INC. | $148.97 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $147.17 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.85 | 2020-2025 | |
| Myovant Sciences INC. | $109.01 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cuellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.